PAVmed Dirección

Dirección controles de criterios 2/4

El CEO de PAVmed's es Lishan Aklog , nombrado en Jun 2014, tiene una permanencia de 9.83 años. compensación anual total es $1.45M, compuesta por 62.1% salario y 37.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.1% de las acciones de la empresa, por valor de $665.22K. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 9.3 años, respectivamente.

Información clave

Lishan Aklog

Chief Executive Officer (CEO)

US$953.2k

Compensación total

Porcentaje del salario del CEO	95.8%
Permanencia del CEO	9.9yrs
Participación del CEO	4.0%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lishan Aklog en comparación con los beneficios de PAVmed?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$953k	US$913k	-US$66m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$79m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$1m	US$901k	-US$89m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$9m	US$583k	-US$51m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$1m	US$431k	-US$35m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$890k	US$431k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$772k	US$346k	-US$19m
Sep 30 2018	n/a	n/a	-US$12m
Jun 30 2018	n/a	n/a	-US$14m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$444k	US$297k	-US$10m

Compensación vs. Mercado: La compensación total de Lishan($USD1.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Lishan ha sido consistente con los resultados de la empresa en el último año.

CEO

Lishan Aklog (57 yo)

9.9yrs

Permanencia

US$953,200

Compensación

Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lishan Aklog	Chairman & CEO	9.9yrs	US$953.20k	3.98% $ 845.6k
Dennis McGrath	President & CFO	7.2yrs	US$673.50k	0.54% $ 114.4k
Shaun O'Neill	Executive VP & COO	2.3yrs	US$498.00k	0.19% $ 40.3k
Michael Gordon	Executive VP	2yrs	US$710.50k	0% $ 0
Brian deGuzman	Executive VP	1.1yrs	US$593.10k	0.048% $ 10.2k
Suman Verma	Senior VP of Molecular Genetics & Chief Scientific Officer	1.3yrs	sin datos	sin datos
Michael Parks	Vice President of Investor Relations	no data	sin datos	sin datos
Deepika Lakhani	Senior VP	1.3yrs	sin datos	sin datos
Victoria Lee	Senior VP & Chief Medical Officer	1.3yrs	sin datos	sin datos

1.7yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PAVM no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lishan Aklog	Chairman & CEO	9.9yrs	US$953.20k	3.98% $ 845.6k
Ronald Sparks	Independent Director	9.3yrs	US$251.90k	0.69% $ 146.2k
Todd Rosengart	Member of Medical Advisory Board	9.5yrs	sin datos	sin datos
Timothy Baxter	Independent Director	2.9yrs	US$238.90k	0.69% $ 146.2k
James Cox	Independent Director	9.3yrs	US$228.90k	0.69% $ 146.2k
Marc Gerdisch	Member of Medical Advisory Board	9.5yrs	sin datos	sin datos
Philip Stieg	Member of Medical Advisory Board	9.3yrs	sin datos	sin datos
Albert Chin	Member of Medical Advisory Board	9.3yrs	sin datos	sin datos
Michael Glennon	Independent Vice Chairman	9.6yrs	US$228.90k	3.34% $ 708.7k
Timothy Murphy	Member of Medical Advisory Board	9.5yrs	sin datos	sin datos
Debra White	Independent Director	3.1yrs	US$248.90k	0.69% $ 146.2k
Christopher Hartnick	Member of Medical Advisory Board	7.5yrs	sin datos	sin datos

9.3yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de PAVM se considera experimentada (9.3 años de antigüedad promedio).

PAVmed Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Independent Vice Chairman recently bought US$161k worth of stock

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Recent updates

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering

New 90-day high: US$2.13

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $8.1 million.

PAVmed closes additional direct offering of common stock

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

PAVmed offers stock for $8.9M

New 90-day high: US$2.06

PAVmed EPS beats by $0.02

New 90-day low: US$1.73

There Is Progress At PAVmed, But More Patience Is Required

New 90-day low: US$1.76

New 90-day low - US$1.80